← FDA DRUG APPROVALS

FDA NDA · NDA020588

RISPERIDONE

Sponsor: JANSSEN PHARMS

APPLICATION
NDA020588
TYPE
NDA
ORIGINAL APPROVAL
1996-06-10
LATEST ACTION
2025-01-22
ROUTE
ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

RISPERDAL · ReferencePrescription
RISPERIDONE 1MG/ML · SOLUTION · ORAL

Approval history

2025-01-22Labeling · Supplement 74 · standardLabelAP
2022-03-11Labeling · Supplement 73 · standardLetterAP
2021-02-12Labeling · Supplement 71 · standardLetterAP
2020-02-05Labeling · Supplement 72 · 901 requiredLetterAP
2019-01-25Labeling · Supplement 70 · standardLabelAP
2018-07-27Labeling · Supplement 68 · standardLetterAP
2017-02-23Labeling · Supplement 66 · 901 requiredLabelAP
2016-03-01Labeling · Supplement 65 · standardLetterAP
2014-04-28Labeling · Supplement 62 · standardLabelAP
2012-08-02Efficacy · Supplement 53 · standardLetterAP
2012-03-12Labeling · Supplement 55 · standardLetterAP
2011-09-24Labeling · Supplement 48 · standardLetterAP
2011-09-24Labeling · Supplement 54 · standardLabelAP
2011-08-24Labeling · Supplement 47 · standardLabelAP
2011-06-15Labeling · Supplement 52 · standardLetterAP
2010-12-01Labeling · Supplement 51 · 901 requiredLabelAP
2010-08-30Labeling · Supplement 49 · unknownLetterAP
2010-08-30Labeling · Supplement 43 · standardLetterAP
2010-08-30Labeling · Supplement 46 · unknownLetterAP
2010-08-30Labeling · Supplement 50 · unknownLabelAP
2009-07-19Labeling · Supplement 44 · 901 requiredLabelAP
2008-08-14Labeling · Supplement 42 · standardLetterAP
2007-08-22Efficacy · Supplement 37 · priorityLabelAP
2007-08-22Efficacy · Supplement 36 · priorityReviewAP
2006-10-06Efficacy · Supplement 24 · priorityReviewAP
2006-10-06Efficacy · Supplement 29 · standardLetterAP
2006-10-06Efficacy · Supplement 28 · standardReviewAP
2005-08-17Labeling · Supplement 30 · standardLabelAP
2003-12-04Efficacy · Supplement 17 · standardLetterAP
2003-12-04Efficacy · Supplement 18 · standardLabelAP
2003-11-21Labeling · Supplement 23 · standardLetterAP
2003-10-29Labeling · Supplement 16 · standardLetterAP
2003-09-10Labeling · Supplement 21 · standardReviewAP
2002-11-19Labeling · Supplement 15 · standardLetterAP
2002-03-03Efficacy · Supplement 4 · standardReviewAP
2001-10-22Manufacturing (CMC) · Supplement 13 · standardAP
1999-07-02Labeling · Supplement 5 · standardLabelAP
1998-10-08Manufacturing (CMC) · Supplement 9 · standardAP
1998-06-03Manufacturing (CMC) · Supplement 8 · standardAP
1998-05-19Manufacturing (CMC) · Supplement 6 · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →